Accomplished Medical Executive in Molecular
Diagnostics and Precision Medicine Brings Global Experience in
Cutting Edge Oncology Diagnostics
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces the appointment of Maria Fe Paz, M.D. Ph.D., effective
immediately, as a medical affairs consultant in the role of Interim
Chief Medical Officer, with plans to transition her to Chief
Medical Officer of Rosetta Genomics upon receipt of a valid work
visa that supports her planned relocation to the U.S.
Dr. Paz is an accomplished chief medical officer with nearly 15
years’ of experience in the pharmaceutical and biomedical industry,
with demonstrated achievements in molecular diagnostics,
translational and precision medicine.
“We are delighted to welcome Dr. Paz to the Rosetta Genomics
team to lead medical affairs, which is a key area for the Company
as we expand our footprint in precision medicine. Maria’s
significant clinical and corporate experience and her depth of
knowledge in molecular diagnostics, epigenomics, oncology and
biomarkers make her ideally suited to lead our medical efforts.
Importantly, her relationships with key thought leaders in oncology
and global pharmaceutical and biotechnology companies will be a
valuable asset for the Company as we expand our research and
development efforts including our pursuit of predictive biomarkers
in immune-oncology,” commented Kenneth A. Berlin, President and
Chief Executive Officer of Rosetta Genomics.
“I am confident Maria will be an outstanding member of our
executive leadership team as she shares our passion for advancing
personalized medicine in order to enhance quality of life for
patients,” added Mr. Berlin.
Dr. Paz joins Rosetta Genomics from Labceutics and the
Diaceutics Group, where she was the Founder-President and Chief
Medical Officer, respectively. In this role, she combined her
extensive knowledge of the global laboratory landscape and
personalized medicine to establish a global laboratory network for
the successful implementation of companion diagnostics for major
pharmaceutical and diagnostic companies. Prior to joining
Diaceutics and founding Labceutics, Dr. Paz was head of
translational medicine and scientific development at Zeltia SA., a
biopharmaceutical company, where she forged important relationships
with international labs and hospitals, and gained over 10 years’
experience establishing and managing laboratories for molecular
diagnostics and precision medicine. In Dr. Paz’s earlier
experience, she founded and served as the Scientific-Medical
Consultant for Epicure Molecular, where she was responsible for
advising on the pharmacogenetics and molecular diagnostic
strategies for drug and biomarker development to pharmaceutical
companies. Dr. Paz was the Head of the Epigenetics Unit at the
Spanish National Cardiovascular Centre (CNIC), and was the founder
and director of Molecular and Genetic Diagnostics Laboratories in
Hospital de Madrid. She began her career as a principal scientist
at the Spanish Biotechnology Centre (CSIC). Dr. Paz received her
B.A. in Molecular Biology and M.D. at the Universidad Autónoma de
Madrid, and holds a Ph.D. from the Spanish National Cancer Center.
Dr. Paz was a Predoctoral Fellow at the Sydney Kimmel Cancer Center
at Johns Hopkins University and a Postdoctoral Fellow at the
Spanish National Cancer Centre.
Dr. Paz is recognized as an award-winning researcher, authoring
more than two dozen publications in peer-reviewed journals. She
serves as an active member of the American Society of Clinical
Oncology, the European Society of Medical Oncology, and the
American Association of Cancer Research and the Spanish Association
of Cancer Research.
Commenting on her appointment, Dr. Paz said, “I am excited to be
joining Rosetta Genomics at this juncture in its growth trajectory.
Rosetta’s recent acquisition of PersonalizeDx expanded its broad
suite of oncology diagnostics that provides physicians with
critical and objective actionable data to select optimal treatment
options and improve patient outcomes. I look forward to working
with the Rosetta team to help increase awareness of, and demand
for, its clinically important portfolio of high-value molecular
testing services, create new relationships with third parties such
as pharmaceutical, biotech and molecular diagnostic companies as
well as in helping set the course for future research and
development activities leveraging Rosetta’s leading, microRNA
biomarker platforms, all with the aim of bringing truly
personalized medicine to patients.”
Dr. Paz will be providing her services as a consultant through a
third party corporation, until she is granted a valid U.S. work
visa.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based and other
genomic diagnostic testing services offered by Rosetta Genomics.
The Rosetta Cancer Origin Test™ can accurately identify the primary
tumor type in primary and metastatic cancer including cancer of
unknown or uncertain primary (CUP). The Rosetta Lung Cancer Test™
accurately identifies the four main subtypes of lung cancer using
small amounts of tumor cells. The Rosetta Kidney Cancer Test™
accurately classifies the four most common kidney tumors: clear
cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. RosettaGX Reveal accurately classifies indeterminate
thyroid nodules. In the U.S. alone, Rosetta Genomics estimates that
150,000 patients a year may benefit from the Rosetta Cancer Origin
Test™, 62,000 patients a year may benefit from the Rosetta Kidney
Cancer Test™, 222,000 patients a year may benefit from the Rosetta
Lung Cancer Test™ and 150,000 a year may benefit patients from
RosettaGX Reveal. The Company’s assays are offered directly by
Rosetta Genomics in the U.S., and through distributors around the
world. In addition to its proprietary products, the Company markets
the Rosetta Genomics OncoGxOne, OncoGxLung, PGxOne™ and EGFR and
KRAS tests for Admera Health. With the acquisition of
PersonalizeDx, the Company now offers a broader menu of molecular
and other assays for bladder, lung, prostate and breast cancer
patients. For more information, please visit
www.rosettagenomics.com. Parties interested in ordering any of
these tests can contact Rosetta Genomics at (215) 382-9000 ext.
309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company offers core FISH, IHC and PCR-based
testing capabilities and partnerships in oncology and urology that
provide additional content and platforms that complement the
Rosetta offerings. Rosetta’s and PersonalizeDx’s cancer testing
services are commercially available through the Philadelphia, PA-
and Lake Forest, CA-based CAP-accredited, CLIA-certified labs,
respectively. For more information visit
www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including but not limited
to statements relating to Rosetta’s expanding its footprint in
precision medicine, Rosetta expanding its research and development
efforts including our pursuit of predictive biomarkers in
immune-oncology, and Dr. Paz ‘s potential contribution to Rosetta,
the potential increase in awareness and demand for Rosetta’s test
portfolio, Rosetta creating new relationships with third parties,
Rosetta’s future research and development activities bringing
personalized medicine to patients and Dr. Paz actually receiving a
valid U.S. work visa in the allotted timeframe constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta’s Annual Report on Form 20-F for the
year ended December 31, 2014 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Rosetta does
not assume any obligation to update any forward-looking statements
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151104005503/en/
Rosetta GenomicsKen Berlin, 609-419-9003President &
CEOinvestors@rosettagenomics.comorInvestors:LHAAnne Marie
Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024